Lipigon Pharmaceuticals AB Stock

Equities

LPGO

SE0015382072

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:22:38 2024-05-10 am EDT 5-day change 1st Jan Change
0.2795 SEK +1.08% Intraday chart for Lipigon Pharmaceuticals AB -10.27% -35.15%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2024 * 14.8M 1.37M Sales 2025 * 26.8M 2.47M Capitalization 35.34M 3.26M
Net income 2024 * -18M -1.66M Net income 2025 * -25M -2.31M EV / Sales 2024 * 1.06 x
Net cash position 2024 * 19.6M 1.81M Net cash position 2025 * - 0 EV / Sales 2025 * 1.32 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 6
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.42%
More Fundamentals * Assessed data
Dynamic Chart
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Lipigon Pharmaceuticals’ Lipisense Gets Swedish Regulators' Nod for Mid-stage Study MT
The Swedish Medical Products Agency Approves Lipigon's Phase II Study with Lipisense CI
Lipigon Pharmaceuticals AB Announces Lipisense Progressing to Phase II Trials CI
Lipigon Pharmaceuticals AB Reports A Statically Confirms reduction of target protein ANGPTL4 after repeate treatment with Lipisense ® CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Lipigon Applies for Clinical Trial Phase II for Lipisense CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Lipigon Pharmaceuticals AB Announces Positive Safety Results and Encouraging Target Engagement Data from the Phase I Lipisense Trial CI
Lipigon Pharmaceuticals Surges 40% on Lipisense Development, Licensing Deal in China MT
Lipigon Announces Development and License Agreement with Leaderna Therapeutics Ltd CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Lipigon Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Lipigon Announces Further Positive Data from Phase I Trial of Lipisense CI
More news
1 day+1.08%
1 week-10.27%
Current month-17.79%
1 month-7.14%
3 months-36.33%
6 months-53.10%
Current year-35.15%
More quotes
1 week
0.25
Extreme 0.251
0.31
1 month
0.25
Extreme 0.251
0.40
Current year
0.25
Extreme 0.251
0.54
1 year
0.25
Extreme 0.251
0.82
3 years
0.25
Extreme 0.251
10.50
5 years
0.25
Extreme 0.251
12.00
10 years
0.25
Extreme 0.251
12.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 10-04-05
Chairman 67 11-12-31
Director of Finance/CFO 54 22-12-31
Members of the board TitleAgeSince
Chairman 67 11-12-31
Director/Board Member 52 20-12-31
Director/Board Member 64 22-12-31
More insiders
Date Price Change Volume
24-05-10 0.2795 +1.08% 288,830
24-05-08 0.2765 -0.90% 119,978
24-05-07 0.279 -7.00% 687,618
24-05-06 0.3 -3.69% 584,077
24-05-03 0.3115 -1.27% 642,485

Delayed Quote Nasdaq Stockholm, May 10, 2024 at 11:22 am EDT

More quotes
Lipigon Pharmaceuticals AB is a Sweden-based project portfolio company. Lipigon's business concept is to develop medicines with new, unique mechanisms of action (so-called first-in-class) for diseases that lack adequate treatment. The Company develops medicines with a focus on diseases where the body's ability to handle fats is disturbed, so-called lipid-related diseases, and where there are unmet medical needs. Initially, the Company's development focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in the clinical development. It creates the conditions for studies with fewer patients and a shorter path to market approval and thus a reduced development risk.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Chiffre d''affaires - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW